629 results on '"Neeland, Ian J."'
Search Results
102. Supplement to: HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
103. Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study
104. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
105. Abstract 12439: Sex-Specific Associations Between Adipose Depots With Subclinical Coronary Atherosclerosis and Cardiovascular Risk
106. Abstract 13892: The Impact of Cardio-Renal Comorbidities on Medical Spend in Patients With Diabetes: A Contemporary Analysis of a Large Accountable Care Organization
107. Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study)
108. Cardiovascular Outcomes Trials for Weight Loss Interventions: Another Tool for Cardiovascular Prevention?
109. Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study)
110. Does abdominal obesity influence immunological response to SARS-CoV-2 infection?
111. Effects of Empagliflozin Treatment on Cardiac Biomarkers in Adults With Metabolically Healthy Obesity: Results From a Randomized, Placebo-Controlled Clinical Trial
112. Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
113. Metabolic Effects of Exercise Training Among Fitness-Nonresponsive Patients With Type 2 Diabetes: The HART-D Study
114. Additional file 1 of Regional adiposity, cardiorespiratory fitness, and left ventricular strain: an analysis from the Dallas Heart Study
115. HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
116. Abstract 016: Association Of Fat Mass, Lean Mass, And Waist Circumference With Risk Of Heart Failure Among Community Dwelling Adults
117. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
118. Taking a ‘stand’ against cardiovascular disease in the era of COVID-19
119. Tipping the Scales for Older Adults: Time to Consider Body Fat Assessment and Management for Optimal Atherosclerotic Cardiovascular Disease and Stroke Prevention?
120. Eliminating Missed Opportunities for Patients with Type 2 Diabetes
121. Capítulo 4 - Diabetes: principales marcadores de lesión y pronóstico
122. 21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient
123. Association of Body Mass Index and Age With Morbidity and Mortality in Patients Hospitalized With COVID-19
124. Prevention and Treatment of Heart Failure
125. Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index
126. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
127. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
128. List of contributors
129. Measures of Adiposity and Fat Distribution and Risk of Diabetes—Reply
130. Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults
131. Temporal Changes in Body Fat Distribution and Hypertension
132. Chapter 4 - Diabetes: Key Markers of Injury and Prognosis
133. Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES
134. Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure
135. Effects of Empagliflozin Treatment on Glycerol‐Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial
136. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
137. Aging and Diabetes: Shifting the Risk Trajectory With High-Sensitivity Cardiac Troponins
138. Unfavorable perceived neighborhood environment associates with less routine healthcare utilization: Data from the Dallas Heart Study
139. EMPAGLIFLOZIN REDUCES ENDOGENOUS GLYCEROL-DEPENDENT HEPATIC GLUCONEOGENESIS IN VISCERALLY OBESE ADULTS WITHOUT TYPE 2 DIABETES MELLITUS
140. The association of lymphotoxin-beta receptor with the subsequent diagnosis of incident gastrointestinal cancer: results from the Dallas Heart Study
141. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease
142. Coronary angiographic scoring systems: An evaluation of their equivalence and validity
143. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
144. Multi-compartment mesenchymal tissue segmentation in pelvic MRI examinations of women: Anthropomorphic and clinical correlations
145. Effect of Exercise and Pharmacological Interventions on Visceral Adiposity: A Systematic Review and Meta-analysis of Long-term Randomized Controlled Trials
146. Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans
147. Abstract 17187: The Association of Longitudinal Patterns of Metabolic Syndrome With Elevated hs-cTnT: The Atherosclerosis Risk in Communities (ARIC) Study
148. Association between neighborhood-level socioeconomic deprivation and incident hypertension: A longitudinal analysis of data from the Dallas heart study
149. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
150. Second-year results from CINEMA: A novel, patient-centered, team-based intervention for patients with Type 2 diabetes or prediabetes at high cardiovascular risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.